Citi raised the firm’s price target on Royalty Pharma (RPRX) to $42 from $40 and keeps a Buy rating on the shares as part of a Q2 earnings preview for the biotechnology group. The firm says Q2 is typically seasonally strong for the large biopharma names.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RPRX:
- Royalty Pharma Strengthens Board with New Appointments
- Royalty Pharma appoints Ho, Weatherman to board of directors
- Royalty Pharma price target raised to $54 from $51 at Morgan Stanley
- Strategic Financial Agreements and Promising Drug Developments Justify Buy Rating for Royalty Pharma
- Royalty Pharma’s Strategic Partnership with Revolution Medicines: A High-Reward Investment Opportunity